NovaBay Pharmaceuticals (NYSE:NBY) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a research report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 4.8 %

Shares of NBY stock opened at $0.57 on Tuesday. The company has a 50 day moving average price of $0.67 and a 200-day moving average price of $1.39. NovaBay Pharmaceuticals has a 52 week low of $0.36 and a 52 week high of $10.73. The firm has a market capitalization of $2.81 million, a PE ratio of -0.01 and a beta of 0.69.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.